Alerts will be sent to your verified email
Verify EmailCAPLIN POINT
Caplin Point Lab
|
Gufic Biosciences
|
Gland Pharma
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
38.0 . | n/a | 346.0 . |
Number of ANDA's Approved By USFDA
|
25.0 . | n/a | 279.0 . |
R&D as a % of Total Sales
|
4.04 % | 1.06 % | 4.8 % |
Financials
|
|||
5 yr Average ROE
|
22.25 % | 26.14 % | 16.21 % |
5yr average Equity Multiplier
|
1.17 | 2.82 | 1.1 |
5yr Average Asset Turnover Ratio
|
0.76 | 1.1 | 0.54 |
5yr Avg Net Profit Margin
|
24.85 % | 9.03 % | 26.8 % |
Price to Book
|
4.95 | 8.41 | 3.43 |
P/E
|
23.44 | 39.03 | 43.23 |
5yr Avg Cash Conversion Cycle
|
64.48 Days | -18.02 Days | 141.92 Days |
Inventory Days
|
54.23 Days | 77.22 Days | 117.9 Days |
Days Receivable
|
88.48 Days | 81.36 Days | 97.99 Days |
Days Payable
|
76.0 Days | 175.58 Days | 98.36 Days |
5yr Average Interest Coverage Ratio
|
513.03 | 10.3 | 245.99 |
5yr Avg ROCE
|
27.4 % | 33.27 % | 21.37 % |
5yr Avg Operating Profit Margin
|
34.96 % | 17.37 % | 39.34 % |
5 yr average Debt to Equity
|
0.01 | 0.73 | 0.0 |
5yr CAGR Net Profit
|
16.34 % | 29.43 % | 0.21 % |
5yr Average Return on Assets
|
19.05 % | 10.17 % | 14.66 % |
Shareholdings
|
|||
Promoter Holding
|
70.62 % | 72.51 % | 57.86 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
1.59 % | 6.76 % | -0.39 % |
Change in Mutual Fund Holding (3 Yrs)
|
0.61 % | -6.16 % | 12.81 % |
Caplin Point Lab
|
Gufic Biosciences
|
Gland Pharma
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Distribution Channel
|
Distribution Channel
|
-
|
Distribution Channel
|
Manufacturing Break-Up
|
Manufacturing Break-Up
|
-
|
-
|